| Document |
Document Title |
|
WO/2024/101337A1 |
Provided in one embodiment is a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing a splicing abnormality that causes onset or advance of a disease. The present disclosure provides in one embodiment a compoun...
|
|
WO/2024/101869A1 |
The present invention relates to a novel compound and an organic light-emitting device comprising same.
|
|
WO/2024/101687A1 |
The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of the organic light-emitting element.
|
|
WO/2024/101948A1 |
The present specification relates to a compound expressed by chemical formula 1, and an organic light-emitting element comprising same.
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/099517A1 |
The invention relates to salts of 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. A compound of general formula (IA) or (IB) is provided, where A represents -C=C- and n is 0 or 1; R1 is selected from among the group consisting of...
|
|
WO/2024/099519A1 |
The invention relates to 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. According to the invention, the derivatives comprise a compound of the general formula (I), wherein A represents -C=C- or -C=C-C=C-; R1 is selected from the...
|
|
WO/2024/101336A1 |
One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
|
|
WO/2024/100402A1 |
Compound(s) according to formula (I), L1-R-L2; wherein L1 is a ligand capable of binding to kinesin family member C1 (KIFC1) as defined herein, R is a linker group with a chain length having an integer of at least 3 atoms; and L2 is a li...
|
|
WO/2024/099516A1 |
The invention relates to cyclized 3-acetyl-4-hydroxybicyclo[3.3.1]non-3-en-2,9-dion derivatives, using a compound of the general formula (IA) or (IB), wherein the bond between X and Y is a single or double bond, with the proviso that if ...
|
|
WO/2024/100115A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/102886A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
|
|
WO/2024/097855A2 |
The present disclosure provides compounds of the formulae herein (e.g., Formulae (I) and (II)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds,...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/094827A1 |
The present invention relates to protein ligands against Carbonic Anhydrase IX (CAIX) as target of biomedical relevance. In particular, the highly specific ligands may be able to exclusively interact with antigens expressed on the surfac...
|
|
WO/2024/097228A1 |
The present disclosure provides compounds of Formula (I), Formula (II), and Formula (III), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, or prodrugs thereof. The provided compounds may be kinase (e....
|
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/090775A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
|
WO/2024/091024A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/089216A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2024/088991A1 |
The present invention relates to heterocyclic compounds of formula (I) capable of activating STING (Stimulator of Interferon Genes).
|
|
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
|
WO/2024/085607A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2024/085354A1 |
The present invention provides, in the present specification, a heterocyclic compound and an organic light-emitting device including same.
|
|
WO/2024/085372A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device and a composition for an organic layer, each including same.
|
|
WO/2024/083255A1 |
Disclosed in the present invention are an SOS1 degradation agent and a user thereof. The present invention provides a compound as represented by formula (I), and/or a stereoisomer, an enantiomer, a diastereomer, a deuterated compound, a ...
|
|
WO/2024/084186A1 |
The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
|
|
WO/2024/085588A1 |
The present invention relates to: a compound for an organic optoelectronic device, represented by chemical formula 1; and an organic optoelectronic device and a display device which comprise the compound. The details of chemical formula ...
|
|
WO/2024/085676A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same, and, more specifically, to an organic compound having excellent electron injection and transport ability and thermal stability...
|
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/078287A1 |
The present application relates to the technical field of organic electroluminescence, and relates to an organic compound and an organic electroluminescent device and electronic apparatus using same. The organic compound has the structur...
|
|
WO/2024/080128A1 |
The present invention addresses the problem of providing an actinic ray-sensitive or radiation-sensitive resin composition from which a resist pattern having a small LWR can be formed. An actinic ray-sensitive or radiation-sensitive resi...
|
|
WO/2024/080792A1 |
Provided are a compound, selected from compounds of Formula 1, enantiomers, diastereomers, solvates and hydrates thereof, and pharmaceutically acceptable salts thereof, methods of preparing the same, and use thereof.
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/078513A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/076891A1 |
Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
|
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
|
WO/2024/076117A1 |
The present invention is an organic compound used in an organic layer provided in an organic light-emitting element. In particular, when the organic compound is used in an electron blocking layer of an organic light-emitting element, it ...
|
|
WO/2024/074414A1 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein Q, R2, R3 and U are as defined herein. The invention further relates to herbicidal compositions which comprise a...
|
|
WO/2024/077216A1 |
The disclosure is directed to compounds of Formula I (I). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2024/068950A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/071398A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
|
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/069492A1 |
Intermediates and processes for the preparation of Relugolix, and to pharmaceutical compositions containing Relugolix manufactured by the invented processes.
|
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
|
WO/2024/069007A2 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relat...
|
